Posts

AstraZeneca Signs Three-Year Agentic AI Licensing Deal with Owkin for K Pro Platform

on
AstraZeneca and Owkin announced a three-year licensing agreement for Owkin's K Pro, an autonomous 'AI Scientist' platform. Owkin will develop custom biopharma AI agents to automate research and competitive intelligence, analyzing clinical trials, recruitment trends, outcomes, and patents. K Pro integrates multimodal data from over 800 hospitals and will be embedded into AstraZeneca’s IT infrastructure and workflows. The deal builds on prior collaboration for an AI tool to pre-screen germline BRCA mutations in breast cancer patients. Announcement made on May 13, 2026; financial terms undisclosed. Sources:

Lilly Highlights Low-Dose Zepbound and Foundayo for Long-Term Weight Loss Maintenance

on

Takeda Restructuring: Over 600 US Layoffs Amid $1.3B Transformation Plan

on

Merck KGaA Axes SpringWorks Pipeline Assets Amid Pipeline Clear-Out While Pursuing M&A for External Innovation

on

BridgeBio's Attruby Challenges Pfizer's Tafamidis in ATTR-CM with Late-Stage Data Hinting at Superior Survival and Reduced Hospitalizations

on

Alkermes Advances Alixorexton to Phase 3 for Narcolepsy with Strong Mid-Stage Data

on

Rigel Pharmaceuticals Secures Licensing Deal for Arvinas and Pfizer's FDA-Approved Breast Cancer Drug VEPPANU

on

Five Burning Questions for Isomorphic Labs After $2.1B Raise

on

INNOVOTEX Appoints Jonathan Arambula to Executive Chairman

on

Faron to Present New BEXMAB Translational and Clinical Data in HR-MDS at EHA 2026

on

Quest Analytics Appoints Chris Lance as Chief Product Officer to Drive AI Innovation

on

Biotech's IPO Tide Turning Amid M&A Surge

on

Viewpoints: How iRhythm Technologies is Patching into the Future of Arrhythmia Detection

on